Thomas Chen Buys 5,556 Shares of Neonc Technologies (NASDAQ:NTHI) Stock

Posted by Brenda Bartman on Sep 15th, 2026

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) CEO Thomas Chen bought 5,556 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were purchased at an average price of $3.60 per share, with a total value of $20,001.60. Following the purchase, the chief executive officer owned 19,261 shares of the company’s stock, valued at approximately $69,339.60. This represents a 40.54% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Neonc Technologies Stock Performance

NASDAQ:NTHI traded down $0.47 during trading hours on Tuesday, hitting $3.31. The company’s stock had a trading volume of 285,988 shares, compared to its average volume of 104,731. The stock has a fifty day moving average of $4.04 and a 200-day moving average of $5.27. Neonc Technologies Holdings, Inc. has a 52-week low of $3.01 and a 52-week high of $12.99.

Neonc Technologies (NASDAQ:NTHI – Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Institutional Trading of Neonc Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTHI. Westmount Partners LLC lifted its position in Neonc Technologies by 355.2% during the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after acquiring an additional 153,858 shares during the period. BlackRock Inc. purchased a new position in shares of Neonc Technologies in the 2nd quarter valued at approximately $815,000. Bank of America Corp DE acquired a new position in shares of Neonc Technologies in the second quarter valued at approximately $1,017,000. Finally, Global Retirement Partners LLC acquired a new position in shares of Neonc Technologies in the second quarter valued at approximately $126,000.

Key Neonc Technologies News

Here are the key news stories impacting Neonc Technologies this week:

Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Weiss Ratings upgraded shares of Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 31st. BTIG Research reaffirmed a “buy” rating and issued a $15.00 target price on shares of Neonc Technologies in a research report on Tuesday, September 8th. Alliance Global Partners began coverage on shares of Neonc Technologies in a research note on Tuesday, May 19th. They set a “buy” rating and a $13.00 price target on the stock. Wall Street Zen cut shares of Neonc Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Maxim Group began coverage on shares of Neonc Technologies in a research note on Monday, May 18th. They issued a “buy” rating and a $20.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Neonc Technologies presently has an average rating of “Hold” and an average target price of $16.00.

Check Out Our Latest Stock Report on Neonc Technologies

About Neonc Technologies

(Get Free Report)

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.